Background: Cyclin-dependent kinase 4 (Cdk4) represents a prime target for the treatment of cancer because most human cancers are characterized by overexpression of its activating partner cyclin D1, loss of the natural Cdk4-specific inhibitor p16, or mutation(s) in Cdk4's catalytic subunit. All of these can cause deregulated cell growth, resulting in tumor formation. We sought to identify a small molecule that could inhibit the kinase activity of Cdk4 in vitro and to then ascertain the effects of that inhibitor on cell growth and tumor volume in vivo. Methods: A triaminopyrimidine derivative, CINK4 (a chemical inhibitor of Cdk4), was identified by screening for compounds that could inhibit Cdk4 enzyme activity in vitro. Kinase assays were performed on diverse human Cdks and on other kinases that were expressed in and purified from insect cells to determine the specificity of CINK4. Cell cycle effects of CINK4 on tumor and normal cells were studied by flow cytometry, and changes in phosphorylation of the retinoblastoma protein 
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The activity of Cdk4 is negatively regulated by p16
INK4A
, hereafter referred to as p16, which acts by binding to Cdk4 and preventing its association with cyclin D1 as well as the subsequent phosphorylation of pRb (6, 11, 12) . p16 can thus be thought of as preventing aberrant activation of Cdk4 under normal conditions. When functional p16 is absent because of mutation, deletion, or transcriptional silencing of the gene, cells undergo unregulated proliferation that results in tumor formation (13, 14) . Conversely, ectopic overexpression of p16 causes cells to arrest in G 1 . This p16-mediated arrest is dependent on the presence of functional pRb (11, (15) (16) (17) . It has been observed that there is a natural inverse relationship between the presence of p16 and pRb in more than 60% of human cancers (18, 19) . In tumors deficient in p16, pRb is always present in an intact and functional form. Unmutated p16 is usually present in tumors that lack functional pRb. Moreover, the majority of human cancers have either constitutively activating mutations in Cdk4 that prevent p16-mediated Cdk4 inhibition or inactivating mutations in p16 itself or they overexpress the Cdk4-activating partner cyclin D1 and/or have lost active pRb (5) . These findings imply that deregulation of Cdk4 activity can cause the unrestricted cell growth that results in tumor formation.
The link between Cdk4 activation and pRb phosphorylation and the crucial role that this pathway plays in cell cycle progression makes Cdk4 an important therapeutic target in cancer. It is conceivable that inhibition of Cdk4 would prevent unregulated growth of cancer cells. That is, a Cdk4-specific inhibitor in a p16-deficient, pRb-positive cell would prevent Cdk4 from phosphorylating pRb, which would lead to a G 1 block in the cell cycle and thereby prevent cell proliferation. Like p16, the inhibitor would have no effect on pRb-deficient cells or on cells that contain inactivated pRb.
Using a recently described screen that identifies novel small molecule inhibitors of Cdk4 activity (20) , we identified CINK4 (a chemical inhibitor of Cdk4) as a compound that specifically inhibits Cdk4 in an in vitro enzyme assay. We have now tested the efficacy of CINK4 as an inhibitor of cell growth in vitro by treating tumor cell lines and in vivo by using an established mouse tumor model.
MATERIALS AND METHODS

Identification of CINK4
A high throughput screen was used to monitor the in vitro phosphorylation of pRb by human recombinant Cdk4/cyclin D1 enzyme purified from insect cells in the presence or absence of compounds from a library of potential small molecule inhibitors of Cdk4 (20) . CINK4 is one such compound that inhibited pRb phosphorylation in this screen.
Chemistry
CINK4 was prepared in a three-step synthesis starting with 2,4,6-trichloropyrimidine. All starting materials were obtained from Fluka (Buchs, Switzerland). 016 mol]) was heated with aqueous ethylamine (100 mL, 70% [1.25 mol]) in a sealed tube at 130°C for 24 hours, yielding yellowish crystals of CINK4 (melting point, 204°C-205°C). The integrity and purity of the final compound and the intermediates were assessed by nuclear magnetic resonance (NMR) spectroscopy ( 1 H-, 13 C NMR, nuclear Overhauser effect) and mass spectrometric and combustion analyses. By these criteria, the CINK4 used in this study was 100% pure.
Kinase Assays
The human cyclins A, B, E, D1, and D2 were co-expressed as glutathione S-transferase (GST) fusion proteins in Sf9 insect cells with the Cdk catalytic subunits (Cdks 1, 2, 4, and 6) as described previously (21) (22) (23) (24) . The holoenzymes, containing a Cdk bound to a GST cyclin, were purified by use of reduced glutathione (GSH)-Sepharose (Amersham-Pharmacia, Zurich, Switzerland). The human tyrosine kinases v-abl, c-met, IGF-1R, and Insulin-R were also expressed as GST fusions in Sf9 cells and were purified over GSH-Sepharose exactly like the Cdk holoenzymes. Kinase reactions were performed as described previously (20, (25) (26) (27) by use of purified tyrosine kinases or the recombinant cyclins complexed with Cdk catalytic subunits in a 1 : 1 ratio in the presence and in the absence of CINK4 by use of the radioactive label [ 33 P]adenosine triphosphate (ATP). GST-pRb(152) (Santa-Cruz Biotechnology, Santa Cruz, CA), which contains the C-terminal 152 amino acid fragment of pRb, was used as a substrate for all Cdk enzyme assays, whereas routinely used protein tyrosine kinase peptide substrates that contain a unique tyrosine residue were used for the specific tyrosine kinase assays (24) (25) (26) (27) . Kinase activity was detected and/or measured by phosphorimage quantitation. All kinase assays were performed in duplicate and represent an average of three independent experiments. Using 10 empirically determined concentrations between 0 and 100 M of CINK4, we determined the concentration of CINK4 that inhibited 50% of the activity of each kinase (IC 50 ). The IC 50 was obtained by plotting the percentage of total radioactive counts incorporated into the substrate by a kinase at a certain concentration of inhibitor compared with total counts incorporated in the absence of CINK4 versus the concentration of the inhibitor.
Interactive Modeling Studies
The modeling work was performed by use of MacroModel version 4.0 software (28) to verify our observations in secondary in vitro enzyme assays that CINK4 inhibits Cdk4 but not Cdk2. Our Cdk4 model is based on the published coordinates of a Cdk2-ATP complex (29) that keeps the Cdk2 amino acid residues within 6 &ARING; of any atom of ATP. We used the sequence alignments reported by Hanks and Quinn (30) to identify the amino acid residues that differed between Cdk4 and Cdk2. Those residues in Cdk2 (Phe 82, Leu 83, His 84, Lys 89, and Gln 131) were then changed in the model to the analogous residues in Cdk4 (His 95, Val 96, Asp 97, Thr 102, and Glu 144, respectively), so that similar rotameric states for the amino acid side chains were maintained.
Interactive docking experiments were performed after ATP was removed from the model and replaced with the structure of CINK4 to determine whether CINK4 could compete with ATP for binding to Cdk4. The orientations of CINK4 and Cdk4 shown in Fig. 1 were considered to be satisfactory because of the strict overlap of the Cdk4/ATP and Cdk4/CINK4 coordinates. The resulting model was energy minimized to find the best nearby conformation [using modified Assisted Model Building With Energy Refinement (AMBER*) software (http://www.amber.ucsf.edu/amber/amber.html) force field with the GB/SA solvation model (31, 32) ] by keeping the amino acids within the ATPbinding site of Cdk4 rigid.
Cell Culture
All cells were cultured at 37°C in 5% CO 2 in medium supplemented with 10% fetal calf serum and 1% penicillin/streptomycin (both from Life Technologies, Inc. [GIBCO BRL], Rockville, MD). U2OS human osteosarcoma and NIH3T3 mouse fibroblast cells were grown in Dulbecco's modified Eagle medium (DMEM) and high glucose (4500 mg/L) with stable glutamine (AMIMED, Allschwil, Switzerland). MRC-5 human fibroblast cells were grown in DMEM and low glucose (1000 mg/L) with stable glutamine (AMIMED).) HCT116 human colon carcinoma cells were grown in McCoy's 5A medium with stable glutamine (AMIMED). U2OS and HCT116 cells lack p16 and express functional pRb (pRb positive and p16 negative), whereas NIH3T3 and MRC-5 cells express functional pRb and p16 (pRb positive and p16 positive).
Exponentially growing cells, representing an asynchronous population, were seeded at a density of 7.5 × 10 4 cells/mL in 10 mL of medium per T75 flask and grown for 24 hours before being treated with CINK4. CINK4 was dissolved in 10% dimethyl sulfoxide (DMSO) to make 100× stock solutions and was added to cells at final concentrations of 5 and 10 M. Cells were then incubated for another 24 hours, after which they were harvested and washed once with phosphate-buffered saline (PBS). For western blotting, the washed cells were then frozen at -80°C. For flow cytometry analyses, washed cells were fixed in 70% ethanol at −20°C overnight and kept at −20°C. For detection of apoptosis, treated cells were harvested, washed with PBS, and fixed with 2% paraformaldehyde for 15 minutes on ice. Cells were washed again with PBS, fixed in 70% ethanol at −20°C overnight, and stored at −20°C. All experiments were performed at least twice under similar conditions to ensure reproducibility.
Quinidine and roscovitine were purchased from Sigma Chemical Co. (St. Louis, MO), and 100× stock solutions of each were prepared in 10% DMSO. Cells were treated with quinidine at a concentration of 50 M for 24 hours to block them in the early G 1 phase of the cell cycle. Serum-starved and mimosinetreated cells were released in the presence of 10 M roscovitine.
Mimosine (CALBIOCHEM AG, Lucerne, Switzerland) was prepared as a 100× stock solution in 10% DMSO and was added to cells at a final concentration of 0.2 mM. Cells were treated for 32 hours with mimosine, after which they were washed and then released into fresh medium lacking mimosine in the presence and absence of CINK4.
MRC-5 and HCT116 cells were serum starved for 72 hours in medium containing 0.1% serum, then released into 10% serum-containing medium with and without 5 and 10 M CINK4 for 24 hours. , and 0.1% Nonidet P-40). Immunoprecipitations were carried out in IP buffer by use of equal amounts of total protein (300 g). The beads were washed eight times with 1 mL of ice-cold IP buffer and 1 mL of ice-cold wash buffer (50 mM Tris-HCl [pH 7.5], 10 mM MgCl 2 , and 1 mM dithiothreitol) before being used for the in vitro Cdk4 kinase assay (using pRb as substrate).
Immunoprecipitation of Cdk4/Cyclin D Complexes
Cell Cycle Analysis
Cells fixed in 70% ethanol were centrifuged for 1 minute at 3000g at 25°C, washed once with PBS, treated with 3 mg/mL ribonuclease (Sigma Chemical Co.) for 30 minutes at 37°C, and stained with 50 g/mL propidium iodide (Sigma Chemical Co.) for 1 hour at room temperature. Flow cytometry analyses were performed on the Becton Dickinson fluorescence-activated cell sortercalibur (Becton Dickinson, Zurich, Switzerland) by use of the Becton Dickinson Cell Quest program. Flow cytometry data were acquired with the use of linear amplification of the fluorescence area measurement (FL-2) and pulse processing (area versus width) to gate on single events, with the total event rate not exceeding 300 events/second. Data acquisition was set to stop after 9 minutes or after a minimum of 10 000 events had been collected in the single-events region.
Apoptosis Detection Assay
The terminal deoxynucleotidyl transferase-mediated bromodeoxyuridine (BrdU) triphosphate nick end-labeling (TUNEL) assay, which detects DNA strand breaks, was performed with the use of the APO-BRDU kit (Phoenix Flow Systems, San Diego, CA) according to manufacturer's instructions to detect apoptosis. Apoptosis was quantified by use of flow cytometry. We also used the Cell Death Detection Enzyme-Linked Immunosorbent Assay kit (Roche Molecular Diagnostics, Basel, Switzerland), according to the manufacturer's instructions to detect DNA fragmentation.
Western Blot Analyses
The frozen cell pellets were thawed and lysed in 100-200 L of RIPA buffer (i.e., 25 mM Tris-HCl [pH 7.5], 1 mM EDTA, 50 mM NaCl, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 0.1% Tween 20, 50 mM ␤-glycerophosphate, 0.2 mM dithiothreitol, 2 mM sodium orthovanadate, 1 mM PMSF, 10 g/mL Antipain, 10 g/mL Leupeptin, and 1× Complete™ Protease inhibitors [Roche Molecular Diagnostics]) at 4°C. The samples were centrifuged for 15 minutes at 4°C at 10 000 rpm. Protein concentrations of the resulting supernatants were determined by use of the Bio-Rad Protein Assay (Bio-Rad, Zurich, Switzerland). Equal amounts of protein (20 g) were separated on 7.5% (for pRb western blots) and 12.5% (for Cdk4, cyclin D1, cdc2, and cyclin A western blots) SDS-polyacrylamide gels and transferred to Immobilon-P Transfer Membrane (Millipore Corp., Zurich, Switzerland). The membranes were probed with the following primary antibodies: Cdk4-Ab (product number sc-260 from Santa Cruz Biotechnology) at 1 : 100 dilution to detect Cdk4; Ab-5 (product number OP-66 from CALBIOCHEM AG) at 1 : 200 dilution to detect phosphorylated and unphosphorylated full-length pRb; C-15 (product number sc-50 from Santa Cruz Biotechnology) at 1 : 2000 dilution to detect the carboxyterminal 15 amino acids of pRb; Ser795 (New England Biolabs, Inc., Basel, Switzerland) at 1 : 200 dilution to detect phosphorylation of pRb at serine residue 795; Ser780 (batch number SZ254 raised at Novartis, Basel, Switzerland) at 1 : 20 dilution to detect phosphorylation of pRb at serine residue 780; and P-Tyr-100 (product number 9411 from New England Biolabs, Inc.) at 1 : 2000 dilution to detect phosphorylation of tyrosine residue 15 in all Cdks. The secondary antibody was horseradish peroxidase-conjugated anti-rabbit immunoglobulin G. Bands were visualized by chemiluminescence by use of the ECL kit (AmershamPharmacia, Zurich, Switzerland).
Detection of Senescence-Associated ␤-Galactosidase
After 24 hours of treatment with CINK4, cells were washed with PBS, fixed in 0.5% glutaraldehyde solution in water for 2 minutes, washed again in PBS, and stained with X-gal solution (i.e., 1 mg/mL X-gal, 0.12 mM K 3 Fe[CN] 6 , 0.12 mM K 4 Fe[CN] 6 , and 1 mM MgCl 2 in PBS [pH 6.0]) overnight at 37°C. Photographs were taken after an overnight incubation at 37°C with the staining solution. All reagents were purchased from Sigma Chemical Co.
In Vivo CINK4 Experiments
The Ethical Committee of the Cantonese Veterinäramt of Basel Stadt approved all experimental protocols involving animals. Female BALB/c nu/nu (nude) mice (19-21 g in body weight) were obtained from Iffa Credo (L'Arbresle, France).
Adherent HCT116 cells were washed once with Hanks' buffer (Life Technologies, Inc.), treated with 0.25% trypsin, washed again with Hanks' buffer, and adjusted to a final concentration of 1 × 10 7 viable cells/mL in Hanks' buffer based on trypan blue staining. This suspension (0.1 mL) was injected subcutaneously into each of 24 mice (eight mice per treatment group). Twenty days later, when tumors derived from those cells had reached a volume of approximately 100 mm 3 , the actual tumor volumes were measured by use of calipers, and those values were used to estimate tumor volume according to the formula: volume (mm 3 ) ‫ס‬ length (mm) × width (mm 2 ) × /6. The mice were then placed into three groups containing eight mice each, the groups were randomly assigned with respect to treatment, and treatment with CINK4, 5-fluorouracil, or control was initiated. CINK4 was administered by intraperitoneal injection at a dose of 30 mg/kg every 12 hours, while 5-fluorouracil (Roche Pharma Schweiz, Reinach, Switzerland) was administered by intravenous injection into a lateral tail vein at a dose of 75 mg/kg once per week. Mice in the control group received the CINK4 diluent (5% DMSO, 0.05% Tween 80, and 95% physiologic saline) by intraperitoneal injection. All treatments were administered at a constant volume (10 mL/kg) for 29 days. Tumor volumes were measured by a blinded procedure at 2-4-day intervals throughout the treatment period. Body weights (in g) were also measured at the same frequency. There was one death, which occurred in the CINK4 treatment group, on the final day of the experiment.
Statistical Methods Used for Analyses of In Vivo Results
We determined the efficacy of various in vivo treatments by calculating the change in tumor volume over time. Because changes in tumor volumes were not always normally distributed, the data were logarithmically transformed to a normal distribution. One-way analysis of variance (ANOVA) by use of Dunnett's test was used to compare changes in tumor volumes in mice treated with CINK4 or 5-fluorouracil with those in the control animals. The influence of treatment on tumor growth rate was determined by comparing the slopes of a plot of log tumor volume versus time from each mouse by one-way ANOVA by use of the two-sided Student's t-Newman-Keuls tests for multiple pairwise comparisons of all groups. The differences between final and initial body weights were compared, by use of two-sided paired Student's t tests, to determine that these differences were distributed normally. For all tests, the level of significance was set at P<.05. Note that, for these small sample sizes, the desired power level of 0.8 was not always obtained. Statistical calculations were performed by use of SigmaStat 2.03 (Jandel Scientific, San Rafael, CA). Statistical tests were twosided.
RESULTS
Selective Inhibition by CINK4
We identified CINK4 in a high throughput screen for small molecules that could inhibit the phosphorylation of a pRb substrate by Cdk4 (20) . CINK4 was prepared subsequently in a three-step synthesis that yielded a product that was 100% pure (see the "Materials and Methods" section). To ascertain whether the inhibitory activity of CINK4 was selective for Cdk4, we determined the concentrations of CINK4 at which the activities of five purified Cdks and four purified tyrosine kinases were 50% inhibited (IC 50 ) by performing in vitro kinase assays in the presence of increasing concentrations of CINK4 by use of purified peptides as substrates (26) (27) (28) (29) . As shown in Table 1, CINK4 showed approximately fourfold more specificity toward Cdk4/cyclin D1 than toward Cdk6/cyclin D1, as determined by IC 50 s. Of interest, the concentrations of CINK4 required to inhibit the kinase activities of Cdk4 and Cdk6 when these kinases were complexed with cyclin D2 were at least an order of magnitude greater than those required to inhibit these kinases when they were complexed with cyclin D1. This difference may reflect alterations in the three-dimensional structures of Cdks that could result from the binding of different cyclins (3) (Table 1 ).
CINK4 and Molecular Modeling Studies
To confirm our experimental observations about the selectivity of CINK4 for Cdk4, we developed a hypothesis for the binding of CINK4 to Cdk4 that was based on interactive docking experiments that modeled theoretical interactions between CINK4 and Cdk4 (35) . Because the structure of Cdk4 has not yet been determined, we developed a theoretical model of its structure that was based on the x-ray crystal structure of the homologous enzyme Cdk2. Like ATP, CINK4 interacts with Cdk4 at the ATP-binding pocket through hydrogen bonds with residues Glu 94 and Val 96 within the Cdk4 kinase hinge region (Fig. 1) . According to this model, selective binding of CINK4 to Cdk4 may depend on its interactions with two Cdk4 residues, Thr 102 and Glu 144, which do not occur at comparable positions in Cdk2. We assume that the phenyl group of the benzylic moiety of CINK4 contacts Cdk4 through the side chain of Thr 102. A similar contact with Cdk2, which contains a bulkier lysine residue in the analogous position, would presumably be prevented by steric hindrance. We also assume that the hydroxy group of CINK4 donates a hydrogen bond to the carboxylate function of Glu 144 in Cdk4. In contrast, the analogous residue in Cdk2 is a glutamine with a weaker potential to accept hydrogen bonds. Further confirmation of our model for the CINK4-Cdk4 interaction comes from kinetic analysis, which indicates that CINK4 inhibits Cdk4 by competing with ATP for binding (data not shown).
Effects of CINK4 on Asynchronous Cells
Results from the in vitro enzyme assays led us to believe that, if CINK4 was a specific inhibitor of Cdk4, then it should block growth of asynchronous cells in the G 1 phase of the cell cycle. We, therefore, tested the effects of CINK4 on two different asynchronously growing cell lines: U2OS cells derived from a human osteosarcoma, which lack p16 (p16 negative), and normal human fibroblast-derived MRC-5 cells, which express p16 (p16 positive). U2OS and MRC-5 cells, which both express functional pRb (pRb positive), were treated with 5 and 10 M CINK4 for 24 hours. These concentrations of CINK4 were used because the concentrations of CINK4 that caused 50% inhibition of growth of a large panel of cell lines were between 5 and 10 M (Soni R, Chaudhuri B: unpublished data). Flow cytometry analyses of cells treated with CINK4 showed that both U2OS and MRC-5 cells arrest in G 1 of the cell cycle, as shown by an increase in the G 0 -G 1 /S ratio (Fig. 2) . However, the block at G 1 was more profound in MRC-5 cells, which express the natural inhibitor of Cdk4, p16. A similar G 1 block was observed in CINK4-treated HCT116 cells (p16 negative and pRb positive; data not shown). The Cdk4 enzyme was immunoprecipitated from CINK4-treated (5 and 10 M) HCT116 cells and its kinase activity, as monitored by levels of pRb phosphorylation, were substantially less than the kinase activity of Cdk4 enzyme immunoprecipitated from untreated cells (data not shown).
We also analyzed the effect of CINK4 treatment on phosphorylation of endogenous pRb, which is a natural substrate of Cdk4. Treatment of U2OS and MRC-5 cells with 5 and 10 M CINK4 reduced hyperphosphorylation of pRb, thereby presumably maintaining pRb in an active state ( Fig. 2 ; western blot panels Ab-5 and C-15). CINK4 treatment also caused these cells to incorporate less BrdU into their DNA (data not shown). This result further suggested that pRb in the CINK4-treated cells had undergone a reduction in hyperphosphorylation, because hyperphosphorylation of pRb is necessary for cells to enter S phase and BrdU can be incorporated only when new DNA is synthesized in S phase. Treatment of U2OS and MRC-5 cells with CINK4 also reduced phosphorylation of pRb at serine residues 780 and 795, two sites that are specifically phosphorylated by Cdk4 (23,36,37) (Fig. 2) . We observed no changes in the levels of Cdk4 in cells that were treated with either concentration of CINK4 (Fig. 2) . CINK4 treatment of the human colon carcinoma cell line HCT116, which is p16 negative and pRb positive, gave similar results (data not shown). These observations suggest that CINK4 could function as an inhibitor of Cdk4 in these cells.
Effects of CINK4 Following Serum Starvation and Quinidine Block
Cdk4 is thought to be the first cyclin-dependent kinase that is activated at the G 1 /S transition. Cdk4 activation initiates phosphorylation of pRb, which leads to a cascade of events that result in the inactivation of pRb and entry of cells into S phase. The transition from G 0 (quiescence) to the G 1 phase of the cell cycle is dependent on serum growth factors: When cells undergo serum starvation, they arrest at the G 0 /G 1 boundary. When fresh serum is added to such cells, they re-enter the cell cycle. We hypothesized that, if CINK4 inhibits Cdk4 in vivo, serumstarved cells should not re-enter the cell cycle when they are exposed to fresh medium containing serum and CINK4. Flow cytometric analyses showed that serum-deprived HCT116 (p16 negative and pRb positive) and MRC-5 (p16 positive and pRb positive) cells remained arrested at G 0 or G 1 after they were released into serum-containing medium containing 5 or 10 M CINK4 (Fig. 3, A and B) . Western blot analyses showed that treatment of the serum-deprived cells with CINK4 also inhibited the phosphorylation of pRb at serine residues 780 and 795 that normally occurs when serum-deprived cells are returned to serum-containing medium (Fig. 3, A and B) . Because Cdk4 has been implicated as the kinase that specifically phosphorylates these sites, these results provide further support that CINK4 acts as a specific inhibitor of Cdk4 in these cells (23, 36, 37) .
To further confirm that CINK4 prevents cells that are blocked in early G 1 from re-entering the cell cycle, we treated U2OS cells with the potassium/sodium channel blocker quinidine for 24 hours to inhibit cell growth (38) and asked if CINK4 would prevent these cells from entering the cell cycle when they were released into fresh media lacking quinidine. Flow cytometry analyses showed that U2OS cells that were released from a quinidine block into medium containing 10 M CINK4 failed to enter S phase, while cells released into medium lacking CINK4 did enter S phase (Fig. 3, C) . Together, these cell culture results support the hypothesis that CINK4 may act by inhibiting the activity of Cdk4.
Effects of CINK4 on Cdk4 Tyrosine Phosphorylation
Dephosphorylation of tyrosine residue 15 in all Cdks activates these enzymes, and, in the specific case of Cdk4, allows cells to progress through the cell division cycle. Conversely, phosphorylation of this tyrosine residue in Cdk4 prevents serumstarved, quiescent cells from re-entering the cell cycle, and the presence of this phosphorylation is also required for G 1 arrest induced by UV irradiation (39, 40) . Fig. 3, D, shows that this inhibitory tyrosine phosphorylation of Cdk4 was present in serum-starved HCT116 cells. We then asked if CINK4 would prevent dephosphorylation of Cdk4 when these cells were transferred to serum-containing medium to induce them to re-enter the cell cycle. Fig. 3 , D, shows that CINK4 treatment maintained the tyrosine phosphorylation on Cdk4 on restimulation of serumstarved HCT116 cells, whereas cells restimulated in the absence of CINK4 lost the tyrosine phosphorylation and re-entered the cell cycle. Roscovitine, by contrast, which inhibits Cdk2 at a later time in G 1 but not Cdk4 (41), failed to maintain tyrosine phosphorylation of Cdk4 on restimulation of serum-starved HCT116 cells (Fig. 3, D) . This result strongly suggests that CINK4 acts by inhibiting Cdk4.
Effects of CINK4 on S-Phase Progression
We predicted that, if CINK4 was a specific inhibitor of Cdk4 activity, treated cells would not be affected once they had entered late G 1 phase and had passed the point in the cell cycle at which Cdk4 activity is required. To test this hypothesis, we treated U2OS cells with mimosine, a nonprotein amino acid from plants that inhibits eukaryotic DNA polymerase ␣, to block them at the G 1 /S boundary (42) and then released the cells from the mimosine block by placing them in fresh medium that lacked mimosine and either contained or lacked CINK4. We then determined the cell cycle profiles at 16 and 38 hours after mimosine was removed from the cells and found that neither 5 nor 10 M CINK4 prevented the cells from proceeding further in the cell cycle (Table 2 ). Cells released in the presence of 5 M CINK4 completed the cell cycle and then arrested at the following G 1 phase. However, cells released from the mimosine block in the presence of 10 M CINK4 completed the cell cycle and then died at the following G 1 phase (Table 2 ). In contrast, mimosine-blocked cells placed in fresh medium lacking mimosine and containing the Cdk2-specific inhibitor roscovitine, which blocks cells at the G 1 /S boundary, did not re-enter the cell cycle (data not shown). These results suggest that CINK4 has little effect on cell cycle progression once cells have entered the late G 1 phase and have proceeded beyond the point in the cell cycle at which Cdk4 activity is required. Therefore, they further confirm the specificity of CINK4 as a Cdk4 inhibitor.
Effect of CINK4 on Induction of Senescence-Associated Markers
Cdk4 inhibition by the Cdk4-specific inhibitory protein, p16, induces senescence (43) (44) (45) (46) . Senescence resembles G 0 , a state that is analogous to terminal differentiation. The induction of senescence-associated markers, such as senescence-associated ␤-galactosidase (SA ␤-gal), in various cancer and normal cells by p16 thus involves inhibition of Cdk4. To determine if CINK4 mimics p16 in its ability to induce senescence, we asked if SA ␤-gal expression was induced in cells that lack functional p16 when they are treated with CINK4. U2OS cells treated with 5 and 10 M CINK4 for 24 and 48 hours were stained to detect SA ␤-gal activity (44) . Approximately 25% of the cells treated with 5 M CINK4 were strongly positive for SA ␤-gal activity, while 10% of the cells were weakly stained (data not shown). In contrast, approximately 5% of the cells treated with 10 M CINK4 for 24 hours expressed SA ␤-gal activity, while longer treatment resulted in considerable cell death. From these results, we conclude that, like p16, Cdk4 inhibition by CINK4 can lead to senescence or apoptosis, depending on the concentration of the inhibitor.
Effects of Prolonged Treatment of Cells With 10 µM CINK4
Prolonged treatment of U2OS cells with CINK4 resulted in considerable cell death. To determine if the U2OS cells were dying by apoptosis, we treated them with 5 and 10 M CINK4 for 48 hours and then subjected them to TUNEL analysis to detect the DNA strand breaks that characterize apoptotic cell death. Fig. 4 shows that a 48-hour treatment of U2OS cells with 5 M CINK4 had little effect on the induction of apoptosis, whereas a 48-hour treatment with 10 M CINK4 resulted in apoptosis in 83% of the cells. These results were qualitatively confirmed by use of a second assay for apoptosis that detects DNA fragmentation (data not shown). The majority of the apoptotic cells were blocked in G 1 . Similar results were obtained by treating HCT116 cells for extended times with 10 M CINK4 (data not shown). Our results suggest that a delicate balance exists between senescence and apoptosis in U2OS and HCT116 cells that are treated with CINK4: Treatment at lower concentrations and for shorter times with this Cdk4 inhibitor causes cells to initiate senescence, whereas prolonged treatment at higher concentrations drives cells into apoptosis. Of interest, p16, a natural Cdk4 inhibitor, behaves similarly in that it induces senescence in some cases and apoptosis in others. This behavior may be due to different levels of p16 being expressed in different cellular contexts (47) .
Effect of pRb on CINK4 Inhibition of Cdk4
The natural Cdk4 inhibitor, p16, mediates its growthinhibitory function via pRb. We, therefore, tested if CINK4 inhibition of Cdk4 was also dependent on functional pRb. For these studies, we used two pairs of cell lines that differed from each other in the means by which pRb was functionally inactivated. The first pair of cell lines consisted of mouse NIH3T3 cells (48) , which have functional pRb (pRb positive), and a congenic cell line that contains a homozygous deletion of pRb (pRb negative); the second pair consisted of U2OS cells and U2OS-TAg, a U2OS-derived cell line that was stably transformed with simian virus 40 large T antigen (49) , which functionally inactivates pRb. Thus, U2OS cells are pRb positive and p16 negative, while U2OS-TAg cells are pRb negative and p16 negative. CINK4 treatment caused a cell cycle block in NIH3T3 pRb-positive cells, while the congenic pRb-negative cells were unaffected (Table 3) . Similarly, U2OS cells (pRb positive) arrested in G 1 on treatment with CINK4, while the U2OS-TAg cells (pRb negative) did not. These results suggest that Cdk4 inhibition by CINK4 requires the presence of functional pRb. This again indicates that, like p16, CINK4 requires pRb to manifest its action.
Effect of CINK4 on Established Tumors
We tested the efficacy of CINK4 as a Cdk4 inhibitor in a mouse xenograft model by using tumors derived from human HCT116 colon carcinoma cells. Initial pharmacokinetic experiments indicated that administration of CINK4 at 30 mg/kg intraperitoneally every 12 hours was sufficient to maintain the concentration of CINK4 in the tumors greater than 0.5 M, a concentration that was necessary to inhibit the growth of those cells in vitro by 50% (data not shown). CINK4 treatment was initiated 20 days after the subcutaneous injection of HCT116 cells into nude mice, when the tumors had a volume of approximately 100 mm 3 , and was continued for 29 days. Fig. 5 ). However, mice treated for the same length of time with 5-fluorouracil had an even greater reduction in final tumor volume (to 327 mm 3 ; 95% CI ‫ס‬ 175 to 479 mm 3 ). Although CINK4 treatment slowed tumor growth rates by approximately 17% compared with treatment with vehicle control, this reduction in growth rate failed to reach statistical significance by the Dunnett test (P ‫ס‬ .1) but was statistically significant as determined by the less conservative Student's t-Newman-Keuls tests (P ‫ס‬ .028). 5-Fluorouracil had a more dramatic effect, showing an approximately 60% reduction in tumor growth rate compared with controls or CINK4 (P<.001 for both) (Fig. 5, inset) . The mice appeared to tolerate both the CINK4 and the 5-fluorouracil treatments, despite experiencing an approximately 20% reduction in body weight during the course of those treatments. A second independent experiment, which resulted in mean final tumor volumes of 960 mm 3 ) for 5-fluorouracil treatment, confirmed the in vivo antitumor activity of CINK4 against HCT116-derived tumors (P ‫ס‬ .035 for both treatment groups versus controls as analyzed by the Dunnett test). Thus, CINK4 treatment was effective in vivo in inhibiting the growth of tumors derived from cells that lack p16 but possess functional pRb.
DISCUSSION
We show here that CINK4, a triaminopyrimidine derivative, specifically inhibits Cdk4 in an in vitro kinase assay and reduces tumor volume in a mouse model. Cdk4 is the key kinase that, by phosphorylating pRb, is required for cell cycle entry and for cells to emerge from quiescence (40, 50) . It should be noted that, in some systems, the activities of Cdk4 and Cdk6 may be responsible for only a component of the phosphorylation of pRb and that hyperphosphorylation of pRb, which is necessary for its growth-inhibitory effects, requires subsequent phosphorylations by Cdk2 (51) . However, initial phosphorylation by Cdk4 and Cdk6 may nevertheless be required for later Cdk2-mediated actions.
Most human tumors have alterations in the p16/Cdk4/pRb pathway. Tumors deficient in p16 grow unabatedly, presumably because Cdk4 is constitutively active in the absence of its natural inhibitor. Therefore, inhibiting Cdk4 activity in tumors that lack (in median mm 3 ), and the x-axis shows the number of days after HCT116 cells were injected into the mice. The inset shows the tumor volume data plotted on a logarithmic scale. The growth rates (slopes) of tumors from control mice (0.0346 ± 0.00219 SEM) were greater than those of tumors from CINK4-treated (0.0287 ± 0.00106 SEM; P ‫ס‬ .028) or 5-fluorouracil-treated (0.0138 ± 0.00182 SEM; P<.001) mice (by use of the Student's t-Newman-Keuls tests). Panel B: body weights over time. The y axis shows body weights (in mean grams), and the x-axis shows the number of days after HCT116 cells were injected into the mice. In both graphs, the filled circles represent mice treated with vehicle controls, the unfilled circles represent treatment with CINK4, and the filled inverted triangles represent 5-fluorouracil treatment. Bars ‫ס‬ 95% confidence intervals. SEM ‫ס‬ standard error of the mean.
